Form 4: Allogene Therapeutics Director Franz B. Humer Sells 9,221 Shares

Director Franz B. Humer of Allogene Therapeutics sold 9,221 shares of common stock at an average price of $2.16 per share on December 5, 2024.

Summary

• Franz B. Humer, a director at Allogene Therapeutics, sold 9,221 shares of common stock on December 5, 2024.
• The sale was executed at a weighted average price of $2.16 per share.
• The prices ranged from $2.145 to $2.185 per share.
• Following the transaction, Humer directly owns 307,507 shares of Allogene Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a neutral disclosure of a stock sale by a director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This is a routine disclosure of a stock sale by a company director, which is common in the biotech industry. Such transactions are closely monitored by investors for insights into management's view of the company's prospects.

Comparison to Industry Standards

• Insider sales are a common occurrence in publicly traded companies, particularly in the biotech sector where stock options and grants are part of compensation packages.
• The sale by Franz B. Humer is not unusual in terms of volume or price range compared to similar transactions by directors in comparable companies.
• It is important to note that this is a single transaction and does not necessarily indicate a negative outlook on the company's future.

Stakeholder Impact

• The sale of shares by a director may be viewed neutrally by shareholders as it is a common occurrence.
• The transaction does not have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Allogene Therapeutics, Director Share Sale, Form 4, Insider Trading, Stock Transaction, Franz B. Humer